` BAVA (Bavarian Nordic A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

BAVA
vs
OMX Copenhagen 25

Over the past 12 months, BAVA has outperformed OMX Copenhagen 25, delivering a return of 5% compared to the OMX Copenhagen 25's 8% drop.

Stocks Performance
BAVA vs OMX Copenhagen 25

Loading
BAVA
OMX Copenhagen 25
Add Stock

Performance Gap
BAVA vs OMX Copenhagen 25

Loading
BAVA
OMX Copenhagen 25
Difference

Performance By Year
BAVA vs OMX Copenhagen 25

Loading
BAVA
OMX Copenhagen 25
Add Stock

Competitors Performance
Bavarian Nordic A/S vs Peers

OMX Copenhagen 25
BAVA
ABBV
AMGN
GILD
VRTX
Add Stock

Bavarian Nordic A/S
Glance View

Economic Moat
None
Market Cap
13B DKK
Industry
Biotechnology

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BAVA Intrinsic Value
285.21 DKK
Undervaluation 42%
Intrinsic Value
Price
B
Back to Top